What is Citryll?
Citryll is a pioneering biopharmaceutical entity dedicated to redefining the treatment landscape for immune-mediated inflammatory conditions. By focusing on Neutrophil Extracellular Traps (NETs) as a fundamental driver of inflammation, the company is moving beyond traditional symptom management. Instead, Citryll targets the root cause of inflammatory cascades, offering a transformative mechanism that addresses previously unaddressed components of disease pathology. This strategic focus on source-level intervention places Citryll at the forefront of next-generation immunology, attracting significant interest from global pharmaceutical leaders and specialized life sciences investors alike.
How much funding has Citryll raised?
Citryll has raised a total of $127.9M across 3 funding rounds:
Series A
$17.2M
Series B
$20.8M
Series B
$89.9M
Series A (2019): $17.2M with participation from Curie Capital, BrightGene, ModiQuest B.V., and BOM Brabant Ventures
Series B (2020): $20.8M led by Seventure Partners, ModiQuest B.V., BOM Brabant Ventures, BrightGene, and BGV (BioGeneration Ventures
Series B (2024): $89.9M supported by Novartis, Johnson & Johnson Innovation, Forbion, and Curie Capital
Key Investors in Citryll
Novartis
A global pharmaceutical manufacturer headquartered in Switzerland, specializing in developing and producing innovative medications and healthcare solutions across multiple therapeutic areas.
Johnson & Johnson Innovation
A division of the global healthcare giant that partners with entrepreneurs and early-stage businesses to develop transformational healthcare solutions through a network of regional innovation centers.
Forbion
A global life sciences venture capital firm with a strong track record of sourcing, building, and guiding biotech and biopharmaceutical companies from early stages through clinical development.
What's next for Citryll?
With the successful closure of its latest financing round, Citryll is well-positioned to transition into more advanced clinical stages. The strategic backing from industry heavyweights provides not only the necessary capital but also the operational expertise required to navigate complex regulatory environments and scale its therapeutic platform. Moving forward, the company is expected to prioritize the validation of its lead candidates in human trials, aiming to demonstrate the efficacy of its NET-targeting technology. As Citryll continues to mature, the focus will likely shift toward establishing further collaborative partnerships and optimizing its manufacturing processes to support potential commercialization efforts in the global healthcare market.
See full Citryll company page
